Antithrombin Market
According to Intent Market Research, the Antithrombin Market is expected to grow from USD 0.5 billion in 2023 at a CAGR of 7.3% to touch USD 0.8 billion by 2030. The Antithrombin Market is dominated by key players such as Grifols S.A., CSL Behring, Shire Pharmaceuticals (Takeda Pharmaceutical Company), Biocryst Pharmaceuticals, Octapharma AG, Sanofi S.A., Alexion Pharmaceuticals (AstraZeneca), Kedrion Biopharma, WuXi AppTec, Mitsubishi Tanabe Pharma Corporation, Baxalta (Now part of Shire, Takeda), Pfizer Inc., Bayer AG, Novo Nordisk A/S, Hainan Super Pharm.